Thursday, February 25, 2021 6:58:16 PM
Today’s Presentation:
LYNAS RARE EARTHS 1H21 Results
Investor Presentation
26 February 2021
https://www.lynascorp.com/wp-content/uploads/2021/02/210226-HY21-Investor-Presentation-2182562.pdf
LYNAS RARE EARTHS HALF YEAR 2021 RESULTS
https://www.lynascorp.com/wp-content/uploads/2021/02/210226-Lynas-Releases-HY21-Results-2182561.pdf
Interim Unaudited Consolidated Financial Report For the half year ended 31 December 2020
https://www.lynascorp.com/wp-content/uploads/2021/02/210226-Half-Year-Accounts-2182560.pdf
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM